TABLE II.
Results of genotype-matching to clinical trials to date
| Group | Patients tested | Platform | Genotype-matched trial enrolment |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center9 | 12,670 | 341- to 410-gene panel | 527 of 5009 (11%) (>1 year of follow-up) |
| Dana–Farber Cancer Institute and Harvard Cancer Center10 | 3,727 | 275-Gene panel | 16 of 50 (32%) (year 1) |
| Cancer Research Center of Lyon11 | 2,676 | 69-Gene panel and aCGH | 143 of 1,944 (7%) |
| MD Anderson Cancer Centre12 | 2,000 | 11- to 50-gene panel | 83 of 2,000 (4%) |
| Princess Margaret Cancer Centre1 | 1,640 | 23- to 48-gene panel | 92 of 1,640 (6%) |
| Institut Gustave Roussy13 | 1,035 | 30- to 75-gene panel and aCGH | 199 of 1,035 (19%) |
| University of Michigan14 | 556 | WGS, WES, RNA-Seq | 3%–11% |
| U.S. National Cancer Institute, Molecular Analysis for Therapy Choice15 | 5,963 | 141-Gene panel and IHC | 688 of 5,963 (12%) |
aCGH = array comparative genomic hybridization; WGS = whole-genome sequencing; WES = whole-exome sequencing; RNA-Seq = next-generation sequencing technique to reveal the presence and quantity of RNA; IHC = immunohistochemistry.